Lucid Diagnostics

At Lucid Diagnostics, we believe early detection will make esophageal cancer a disease of the past. We're using next generation sequencing to fundamentally change the way esophageal precancer is detected. Our groundbreaking EsoGuard DNA test assesses genes from cells collected from the esophagus in a quick, non-invasive procedure. This gives clinicians the ability to detect disease before it progresses to cancer, all without the need for sedation.

With ~90% sensitivity and ~99% negative predictive value at detecting Barrett's esophagus^1,2,3 and esophageal adenocarcinoma,^1,2 the EsoGuard esophageal DNA test allows detection of these conditions in a simple office-based procedure without endoscopy.¹

LEARN MORE AT ESOGUARD.COM

EsoCheck with Collect+Protect™ Technology is a cell collection device that is designed to collect cells of a targeted region of the esophagus without the need for endoscopy. The sampled cells can then be subjected to any commercially available diagnostic test.

LEARN MORE AT LUCIDDX.COM

Bringing EsoGuard testing to at-risk patients

Nationwide Lucid Test Centers make getting tested easy. At-risk patients can be referred to Lucid staffed test centers for the ~3-minute esophageal cell collection.

1. Moinova, Helen R et al. “Multicenter, prospective trial of non-endoscopic biomarker-driven detection of f Barrett’s Esophagus and Esophageal Adenocarcinoma.” The American Journal of Gastroenterology (2024): 10-14309.
2. Greer, Katarina B et al. “Non-endoscopic screening for Barrett’s Esophagus and Esophageal Adenocarcinoma in at risk veterans.” medRxiv (2024): 2024-03 [Preprint.
3. Shaheen, N., et al., Use of the EsoGuard® Molecular Biomarker Test in Non-Endoscopic Detection of Barrett's Esophagus among High-Risk Individuals in a Screening Population. medRxiv, 2024: p. 2024.06.24.24309401.